This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and
clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients
with unresectable locally advanced or metastatic HER2-positive breast cancer with tumors
harboring PIK3CA mutations, candidates to receive maintenance HP after first line treatment
for metastatic disease with a taxane plus HP
The main objective of the study is to assess whether the combination of ipatasertib and HP
(+/- ET) is tolerable, especially in terms of the incidence and severity of diarrhea. For
this purpose, up to a total of 25 patients will be enrolled in a staggered manner and
A 3-cohort, descending doses (400, 300, 200 mg) design will serve to establish the Maximun
Toleraded Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ipatasertib in combination with
The study will initially include 6 patients that will receive ipatasertib plus HP at Dose
If ≤1 DLTs are observed, this dose will be deemed safe, and the trial will enroll at least
additional 19 patients to further assess safety and preliminary efficacy of the combination.
If ≥2 DLT occurs in the first 6 patients, a decision will be made of whether expand Dose
Level 1 to 10 additional patients or to de-escalate ipatasertib to the next lower dose level.
In the case of de-escalation, the same rules will apply for enrollment and expansion of Dose
level -1. The minimum ipatasertib dose explored will be Dose level -2.
Dose reductions of pertuzumab and trastuzumab will not be allowed.
If all inclusion criteria and no exclusion criteria are met, patients will be enrolled in the
trial and will start treatment with oral (PO) ipatasertib once a day (QD) D1-21 in 28-days
cycles, together with pertuzumab 420 mg intravenous (IV) every 21 days (Q21d) and trastuzumab
600 mg subcutaneous (SC) Q21d.
Patients with hormone receptor positive (HR+) tumors (defined as ER and/or PgR expression in
>1% of tumor cells) will also receive endocrine therapy either an Aromatase Inhibitor (AI),
tamoxifen or fulvestrant +/- Luteinizing Hormone-Releasing Hormone (LHRH) analogues,
according to Investigator's decision.
Patients will also start loperamide (2 mg twice a day [BID] or 4 mg QD) as prophylaxis for
diarrhea in the first cycle
1. Written and signed informed consent for all study procedures according to local
regulatory requirements prior to beginning of specific protocol procedures.
2. Female (pre- or postmenopausal) or male patients.
3. Age ≥ 18 years.
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
5. Confirmed HER2-positive invasive breast cancer by central determination defined by
American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP)
clinical practice guidelines. (Wolff el al. Arch Pathol Lab Med-Vol 142, November
6. Known hormone receptor status, as assessed locally, defined by ASCO/CAP clinical
practice guidelines. ER/PR positivity is defined as the presence of ≥ 1% of tumor
cells with nuclear staining (Hammond et al. JCO 2010).
7. Histologically confirmed, locally advanced or metastatic adenocarcinoma of the breast.
1. Patients with unresectable locally advanced disease must have recurrent or
progressive disease, which must not be amenable to resection with curative
intent. Patients with available standard curative options are not eligible.
2. For patients with bilateral breast cancer, HER2-positivity must be demonstrated
in both locations or in a metastatic biopsy.
8. Patient must be a candidate to receive maintenance HP after first line treatment for
metastatic disease with at least 4 cycles of taxane plus HP.
9. Prior taxane must have been discontinued for a reason other than progressive disease.
10. Patients may or may not have received neo/adjuvant therapy but must have a
disease-free interval from completion of anti-HER2 therapy to metastatic diagnosis ≥6
11. PIK3CA mutation identified and confirmed in tumor tissue or plasma ctDNA by central
12. Start of treatment with ipatasertib plus HP no later than 9 weeks after last dose of
taxane plus HP (i.e., maximum of 2 HP administrations with no taxane).
13. Willingness and ability to provide archived formalin fixed paraffin embedded (FFPE)
14. Measurable or non-measurable (but evaluable) disease, as per RECIST 1.1 criteria.
15. No baseline diarrhea or diarrhea grade ≤1 within the last 28 days.
16. Adequate hematologic and organ function within 14 days before the first study
treatment on Day 1 of Cycle 1, defined by the following:
1. Neutrophils (ANC ≥1500/μL)
2. Hemoglobin ≥9 g/dL (with no need for transfusions in the last 14 days).
3. Platelet count ≥75,000/μL
4. Serum albumin ≥3 g/dL
5. Total bilirubin ≤1.5x the upper limit of normal (ULN), with the exception:
patients with known Gilbert syndrome who have serum bilirubin ≤3x ULN.
6. AST and ALT ≤2.5x ULN, with the following exception: patients with documented
liver or bone metastases who may have AST and ALT ≤5x ULN.
7. ALP ≤2x ULN, with the following exceptions:
- Patients with known liver involvement who may have ALP ≤5x ULN.
- Patients with known bone involvement who may have ALP ≤7x ULN.
8. PTT (or aPTT) and INR ≤1.5x ULN (except for patients receiving anticoagulation
- Patients receiving heparin treatment should have a PTT (or aPTT) between 1.5
and 2.5x ULN.
- Patients receiving coumarin derivatives should have an INR between 2.0 and
3.0 assessed in two consecutive measurements 1 to 4 days apart.
9. Serum creatinine <1.5x ULN or creatinine clearance ≥50 mL/min based on
Cockcroft-Gault glomerular filtration rate estimation:
(140 - age) x (weight in Kg) x 0.85 (if female)/72 x (serum creatinine in mg/dL)
10. Fasting total serum glucose ≤150mg/dL and glycosylated hemoglobin (HbA1C) ≤7.5%
17. Life expectancy of at least 6 months.
18. Baseline left ventricular ejection fraction (LVEF) ≥50% measured by echocardiography
(ECHO) or Multiple Gate Acquisition (MUGA) scan.
19. Negative β-HCG pregnancy test (serum) for premenopausal women of reproductive capacity
(those who are biologically capable of having children) and for women less than 12
months after the menopause. All subjects who are biologically capable of having
children must agree and commit to the use of a reliable method of birth control from 2
weeks before administration of the first dose of investigational product until 28 days
after the last dose of investigational product.
20. Absence of any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule; those
conditions should be discussed with the patient before registration in the trial.
1. Last dose of taxane plus HP given more than 9 weeks prior to C1D1.
2. Prior malignancy within 3 years prior to randomization, except curatively treated
non-melanoma skin, carcinoma in situ of the cervix or Stage I uterine cancer.
3. Brain metastases that have not been treated previously, are progressive, or require
any type of therapy (e.g., radiation, surgery, or steroids) to control symptoms within
30 days prior to the first study treatment dose.
4. Radiotherapy for metastatic sites of disease outside of the brain performed within 14
days prior to study enrollment and/or radiation of >30% of marrow-bearing bone.
5. Symptomatic hypercalcemia requiring use of bisphosphonate or RANKL inhibitors therapy
within 21 days prior to the first study treatment. Patients who receive bisphosphonate
therapy specifically to prevent skeletal events are eligible if they have been
initiated prior to the treatment to study.
6. Cardiopulmonary dysfunction as defined by:
1. Inadequately controlled angina or serious cardiac arrhythmia not controlled by
2. Inadequate LVEF at baseline, as defined as LVEF <50% by either ECHO or MUGA scan.
3. History of symptomatic congestive heart failure (CHF): Grade ≥3 per NCI CTCAE
version 4.03 or Class ≥II New York Health Association (NYHA) criteria.
4. History of a decrease in LVEF to <40% or symptomatic CHF with prior trastuzumab
or HP treatment.
5. History of myocardial infarction within 6 months prior to randomization.
6. Current dyspnea at rest due to complications of advanced malignancy, or other
disease requiring continuous oxygen therapy.
7. Congenital long QT syndrome or screening QT interval corrected using Fridericia's
formula (QTcF) > 480 milliseconds.
8. Concurrent, serious, uncontrolled infections or current known infection with HIV
(testing is not mandatory).
9. History of intolerance, including Grade 3-4 infusion reaction or hypersensitivity, to
trastuzumab or pertuzumab.
10. Known hypersensitivity to any of the study drugs, including excipients.
11. Known clinically significant history of liver disease consistent with Child-Pugh Class
B or C, including active viral or other hepatitis (e.g., positive for hepatitis B
surface antigen [HBsAg] or hepatitis C virus [HCV] antibody at screening), current
drug or alcohol abuse, or cirrhosis.
- Patients with past hepatitis B virus (HBV) infection or resolved HBV infection
(defined as having a negative HBsAg test and a positive antibody to hepatitis B
core antigen [HBcAg] antibody test) are eligible.
- Patients positive for HCV antibody are eligible only if polymerase chain reaction
(PCR) is negative for HCV RNA
12. History of Type I or Type II diabetes mellitus requiring insulin. Patients who are on
stable dose of oral diabetes medication > 2 weeks prior to initiation of study
treatment are eligible for enrollment.
13. Grade ≥2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia.
14. History of or active inflammatory bowel disease (e.g., Crohn's disease and ulcerative
colitis) or active bowel inflammation (e.g., diverticulitis).
15. Lung disease: pneumonitis, interstitial lung disease, idiopathic pulmonary fibrosis,
cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic
infections (Pneumocystis pneumonia or Cytomegalovirus pneumonia).
16. Need for chronic corticosteroid therapy of >10 mg of prednisone per day or an
equivalent dose of other anti-inflammatory corticosteroids for a chronic disease.
17. Uncontrolled pleural effusion, pericardial effusion, or ascites. Patients with
indwelling catheters (e.g., PleurX®) are allowed.
18. Treatment with strong CYP3A inhibitors or strong CYP3A inducers within 2 weeks or 5
drug-elimination half-lives, whichever is longer, prior to initiation of study drug.
19. Prior treatment with an AKT inhibitor. Prior PI3K or mTOR inhibitors are allowed.
20. Current severe, uncontrolled systemic disease (e.g. clinically significant
cardiovascular, pulmonary or metabolic disease; wound healing disorders; ulcers; bone
21. Unresolved, clinically significant toxicity from prior therapy, except for alopecia
and Grade 1 peripheral neuropathy.
22. Major surgical procedure or significant traumatic injury within 28 days prior to
23. Assessment by the investigator to be unable or unwilling to comply with the
requirements of the protocol.
24. History of significant comorbidities that, in the judgment of the investigator, may
interfere with the conduction of the study, the evaluation of response, or with